A COhort Study on Factors Leading to Vulnerability in Adult Patients With Serious Medical cOnditionS: the COSMOS-I Trial

The objective of this prospective multicentre study that recruits altogether 1500 older patients from the university hospitals of Tampere, Kuopio, and Oulu is to explore the clinical significance and detection of causes of generalized vulnerability. The objectives are:

O1 - Establish the prevalence of causes of generalized vulnerability among patients diagnosed with severe yet non-malignant diseases and local/locally advanced and advanced cancers, O2 - Study how causes of generalized vulnerability affect the time between the diagnosis and the adoption of a fully palliative treatment line, overall survival, and patient-reported quality of life in older adults severe diseases, and O3 - Evaluate how screening tools commonly used in patients without cancer perform in screening for causes of vulnerability in older adults with cancer

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Pelvic Fracture Brain Diseases Brain Metastasis Brain Neoplasms Cardiovascular Diseases Central Nervous System Diseases Central Nervous System Neoplasms Cerebrovascular Disorders Chronic Disease Chronic Subdural Hematoma Craniocerebral Trauma Disease Attributes Femoral Fractures Fractures, Bone Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Hematoma Hematoma, Subdural Hematoma, Subdural, Chronic Hemorrhage Hip Fractures Hip Injuries Intracranial Hemorrhage, Traumatic Intracranial Hemorrhages Leg Injuries Lung Cancer Lung Diseases Lung Neoplasms Male Urogenital Diseases Neoplasms Neoplasms by Site Nervous System Diseases Nervous System Neoplasms Pathologic Processes Pathological Conditions, Signs and Symptoms Prostate Cancer Prostatic Diseases Prostatic Neoplasms Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms Trauma, Nervous System Urogenital Diseases Urogenital Neoplasms Vascular Diseases Wounds and Injuries

Sex eligibility

Male

Study type

Observational

Primary location

Tampere University Hospital

Tampere, Finland

Location status: Recruiting

Location contact

Otso Arponen

CONTACT

[email protected]

0504106170 ext. +358

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Suspected or diagnosed disease
≥60 years old patients, except for patients receiving high-dose chemotherapy and stem cell transplantion who need to be ≥18 years old
Cross-sectional imaging maximum 45 days prior to consenting or before the next treatment line
Patients with cancer (other than patients with prostate cancer treated with hormonal treatment before radiation treatment): study procedures (excluding image analyses) must have been carried out maximum 1 month prior to the start of a new treatment line
Patients with prostate cancers receiving hormonal treatment before radiation treatment): study procedures (excluding image analyses) must be carried out maximum 3 months after the start of hormonal treatment
Patients with other conditions: study procedures (excluding image analyses) must have been carried out maximum 4 days after the start of the hospitalization

Exclusion criteria

Not willing or unable to give written consent
Patient not deemed suitable for the study by the researcher approaching the patient

Treatment and study plan

Test set to determine vulnerability

Other

This is a prospective observational study.

Primary outcomes

Detected cause of vulnerability

Time frame: Around the time of study procedure

Study contacts

Contact information is provided by the study sponsor or research team.

Otso Arponen, Adjunct professor, MD

CONTACT

[email protected]

504106170 ext. +358

Sponsors and collaborators

Lead sponsor

Tampere University Hospital

Other

Registry information

Acronym: COSMOS-I

Important dates

Study start: 2024
Primary completion: 2030
Study completion: 2030
First posted: Jul 31, 2026
Registry last updated: Jul 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting